secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axsome Therapeutics, Inc. (AXSM)
CIK:        0001579428
Form:       8-K
Filed at:   2024-06-05T23:59:59+00:00
Accession:  0000950170-24-069077
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axsome settles Sunosi patent litigation with Unichem; generic entry June 30, 2042
--------------------------------------------------------------------------------

- Settlement resolves Hatch-Waxman litigation over Sunosi (solriamfetol) following Unichem's ANDA.
- Unichem may begin selling generic Sunosi on June 30, 2042, subject to pediatric exclusivity extension.
- Agreement subject to FTC and DOJ review; other Sunosi patent cases remain pending in New Jersey.
- Axsome maintains Sunosi exclusivity until at least 2042 unless earlier triggering events occur.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1579428/000095017024069077/0000950170-24-069077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1579428/000095017024069077/axsm-20240605.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-069077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer